Lunan Pharmaceutical Group, with strong innovation and robust talent ecosystem, takes the lead in Shandong's pharmaceutical industry. [Photo/Dazhong News]

Shandong's pharmaceutical industry is at the forefront of innovation in China, with Linyi city's Lunan Pharmaceutical Group leading the charge in Shandong. Recognized as the top innovator among Shandong private enterprises for four consecutive years, Lunan has become a global player with one out of every six sevoflurane anesthetics sold worldwide originating from the company.

Lunan's success is rooted in its commitment to innovation. The company has tackled key technological challenges in traditional Chinese medicine, revitalizing ancient remedies. It has also made significant strides in targeted therapies and biologics, undertaking 34 national research projects and earning 55 provincial-level science and technology awards.

Investing 10 percent of its revenue annually into R&D, Lunan focuses on biopharmaceuticals, innovative drugs, and high-end formulations. Notable achievements include the market launch of the CD20 monoclonal antibody rituximab and the modernization of a classic Chinese medicine formula into a contemporary preparation, which has become a star product in pandemic response.

Lunan has also built a robust talent ecosystem, attracting top-tier researchers and investing over 100 million yuan ($13.94 million) annually in staff training. The company's global "Shennong plan" aims to fill over 1,000 positions, reflecting its dedication to nurturing a young and dynamic R&D team.

To date, with over 90 percent of research outcomes commercialized and more than 2,800 patents granted, the company stands as a beacon of innovation in Shandong's pharmaceutical sector.